Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 20/20 | 0.71 |
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 14/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 13/20 | 0.65 |
| ▸ | PLK4 | O00444 | 1/20 | 0.49 |
| ▸ | CDK2 | P24941 | 1/20 | 0.49 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.49 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.49 |
| ▸ | CSNK1G3 | Q9Y6M4 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5195433 | 0.90 | ADORA2B (0.70) | ADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL4170667 | 0.82 | ADORA2B (0.57) | ADORA2BADORA3ADORA2AADORA1PLK4 | |
| SCHEMBL5140491 | 0.81 | ADORA2B (0.69) | ADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL243681 | 0.79 | ADORA2B (1.00) | ADORA2BADORA3ADORA2AADORA1PLK4 | |
| SCHEMBL3466868 | 0.76 | ADORA2B (0.57) | ADORA2BADORA3ADORA2AADORA1PLK4 | |
| SCHEMBL1546818 | 0.75 | ADORA2B (1.00) | ADORA2BADORA3ADORA2AADORA1PLK4 | |
| SCHEMBL1724705 | 0.75 | ADORA2B (0.58) | ADORA2BADORA3ADORA2AADORA1PLK4 | |
| SCHEMBL1446900 | 0.75 | ADORA2B (0.70) | ADORA2BADORA3ADORA2AADORA1PLK4 | |
| SCHEMBL1944916 | 0.75 | ADORA2B (0.82) | ADORA2BADORA3ADORA2AADORA1PLK4 | |
| SCHEMBL4767372 | 0.74 | ADORA2B (0.68) | ADORA2BADORA3ADORA2AADORA1PLK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996201-A2 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007109547-A2 | METHOD OF PREVENTING AND TREATING HEPATIC DISEASE USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-09-27 | — | — | WO | disclosed |
| EP-1789053-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006028810-A2 | METHOD OF WOUND HEALING USING A2B ADENOSINE RECEPTOR ANTAGONISTS | CV THERAPEUTICS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |